Amferia develops innovative medical devices to provide solutions to the global antibiotic resistance crisis. Amferia's core focus is preventive healthcare where the goal is to provide highly efficient anti-infective medical devices that can prevent bacterial infections including those caused by antibiotic resistant bacteria. Our dominant focus is within the wound care sector, producing preventive care wound patches for the pressing need to avoid antibiotic resistant skin infections. Amferia’s proprietary anti-infective technology is a result of several years of research from Chalmers University of Technology and is patent protected.
A Short Introduction to Amferia at Swedbank’s Rivstart 2018
Antibiotic resistance (ABR) happens when bacteria develops resistance against our antibiotics. This makes simple infections such as skin wound infections lethal. Today, we are in a situation where many types of bacteria has evolved to an extent where, none of our antibiotics work against them. The world health organization estimates ABR to become a leading cause of heathcare threat to humanity by 2050.
Learn more about Antibiotic Resistance
"Projections show the estimated number of causalities around the world from antibiotic resistance by the year 2050" - Sourced from Review on Antimicrobial Resistance, 2014
A common antibiotic resistant bacteria is MRSA or Methicillin Resistant Staph. Aureus. MRSA is a dangerous bacteria that can cause skin infections with life-threatening complications. MRSA is only one of the many strains of bacteria that is resistant to antibiotics today.
Learn more about Antibiotic Resistant skin infections and MRSA.
Antibiotic resistant infections, especially skin infections is a threat to human existence today. This has called for a need for new solutions and new pathways to ensure a sustainable future. At A M F E R I A we believe we can join the fight against antibiotic resistance through a new technology that we have developed for the cause. We envision a healthy and safe future for humanity.
Our Anti-infective Technology
Amferia's proprietary patented technology is a new and effective antibacterial material. The material consists of antibacterial polymers that are able to rapidly kill bacteria upon contact, including antibiotic resistant bacteria. The material is highly selective and targets only bacteria while being entirely non-toxic to human cells. We have today transformed this concept into a first prototype of a preventive wound care patch. Our goal is to develop and bring this concept into the market as a preventive care for patients at risk of acquiring dangerous skin infections.
Today, we have confirmed the efficiency and functionalities of the device against numerous bacterial strains including multiple strains of resistant bacteria. The tests were conducted at Chalmers University of Technology. A prototype of the patch has been developed and a design and scalability analysis is ongoing.
Introducing Amferia's Preventive Wound Care Patch